Trade TGTX anytime, even after market hours
Regulated by
MAS
Trusted by
400,000+ users
TG Therapeutics, Inc. (TGTX) is trading at US$53.93, down 3.21% today as of Aug 28, 16:00 EDT. The company has a market capitalisation of US$8.31B. Over the past 52 weeks, TGTX has traded between US$26.76 and US$59.30. On Syfe you can trade TGTX with $0 commission and add it to your watchlist.
| Previous close | US$55.72 |
|---|---|
| Market cap | US$8.31B |
| P/E ratio | 24.18 |
| 52-week range | US$26.76 – US$59.30 |
| Volume | 1.03M |
| Exchange | US |
Add to Watchlist
Set Price Alert
TG Therapeutics, Inc.
TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.
Year: 1995
B. Riley Raises Price Target on TG Therapeutics to $86 From $55, Keeps Buy Rating
Jul 27, 11:47 AM · MT Newswires
Moderna, TG Therapeutics, Agios Pharmaceuticals Q2 Results May Face Increased Scrutiny, BofA Says
Jul 7, 3:04 PM · MT Newswires
TG Therapeutics, Inc. (TGTX) stock is trading at US$53.93, -3.21% from the previous close of US$55.72.
The market cap for TG Therapeutics, Inc. (TGTX) stock is approximately US$8.31B.
The price-to-earnings ratio for TG Therapeutics, Inc. (TGTX) is 24.18, based on the latest reported earnings.
The 52-week high for TG Therapeutics, Inc. (TGTX) stock is US$59.30.
The 52-week low for TG Therapeutics, Inc. (TGTX) stock is US$26.76.
TG Therapeutics, Inc. (TGTX) does not currently pay a dividend.
Stay on top of TGTX
Price moves, news and earnings — straight to your inbox.
Est. order value
US$0.00
Snapshot
